Pamukçuoğlu Merve, Emmez Hakan, Tunçcan Ozlem Güzel, Oner Ali Yusuf, Cırak Meltem Yalınay, Senol Esin, Sucak Gülsan Türköz
Hematology. 2014 Apr;19(3):158-62. doi: 10.1179/1607845413Y.0000000108. Epub 2013 Nov 25.
Introduction of high-dose chemotherapy and the novel agents including bortezomib, Lenalidomide, and Thalidomide has provided a significant progress in the treatment of multiple myeloma (MM) with an increase in median overall survival up to 6-8 years. However, the advances in myeloma treatment comes at a price with new spectrum of treatment-related infectious complications which should be taken into consideration while treating these patients.
We report here two patients with Ig G λ MM presenting with intracerebral mass lesions in the abscence of constitutional symptoms that would suggest an infectious etiology. Both patients had severe hypogammaglobulinemia and lymphopenia, which was attributed to treatment regimens including bortezomib. Intervention The surgical intervention-revealed abscess in both cases caused by Nocardia cyriacigeorgica, a relatively new pathogen which rarely causes infections in humans and also an unexpected pathogen in myeloma patients.
Although every aspect of immune system is known to be affected in MM, humoral immune deficiency is the hallmark of the inherent immune defect in this disease. Introduction of the novel agents, bortezomib in particular seems to have changed the characteristics of the immune dysfunction and the spectrum of the opportunistic infections by causing qualitative and quantitative changes in cellular immunity. The new spectrum of infectious agents might not be limited to hepatitis B and herpes zoster. Monitoring lymphopenia and administration of prophylactic antimicrobial agents accordingly could be considered in patients treated with bortezomib.
大剂量化疗以及包括硼替佐米、来那度胺和沙利度胺在内的新型药物的引入,在多发性骨髓瘤(MM)治疗方面取得了显著进展,使中位总生存期延长至6至8年。然而,骨髓瘤治疗的进展是有代价的,出现了一系列与治疗相关的感染并发症,在治疗这些患者时应予以考虑。
我们在此报告两名IgG λ型MM患者,他们出现脑内肿块病变,且无提示感染病因的全身症状。两名患者均有严重的低丙种球蛋白血症和淋巴细胞减少,这归因于包括硼替佐米在内的治疗方案。干预:手术干预显示两例均为吉氏奴卡菌引起的脓肿,吉氏奴卡菌是一种相对较新的病原体,很少引起人类感染,也是骨髓瘤患者中意想不到的病原体。
虽然已知MM会影响免疫系统的各个方面,但体液免疫缺陷是该疾病固有免疫缺陷的标志。新型药物的引入,尤其是硼替佐米,似乎通过引起细胞免疫的质和量的变化,改变了免疫功能障碍的特征和机会性感染的范围。感染病原体的新范围可能不限于乙型肝炎和带状疱疹。对于接受硼替佐米治疗的患者,可考虑监测淋巴细胞减少情况并相应给予预防性抗菌药物。